Influence of psychotpropic drugs on the state of lipid and carbohydrate exchange in patients
https://doi.org/10.34680/2076-8052.2022.1(126).81-85
Abstract
The study of indicators of lipid and carbohydrate metabolism in patients taking neuroleptic and psychotropic drugs is currently a very urgent problem. This is explained by an increase in the number of people taking these drugs. The study of the effect of psychotropic therapy on the parameters of lipid metabolism, lipid peroxidation processes, and the state of carbohydrate metabolism at various values of the neuroleptic load is of particular interest. The article describes the impact of typical and atypical psychotropic drugs on lipid and carbohydrate metabolism in patients requiring psychiatric care. Particular attention is paid to the effect of drugs from the group of atypical antipsychotics on metabolic parameters. The article is devoted to elucidating the effect of antipsychotic drugs on weight gain, the development of diabetes, and other metabolic disorders, which often lead to a deterioration in the clinical course of the disease and the state of health of patients. Despite the fact that various changes in metabolism have been studied by many authors, the mechanisms of these changes have not yet been finally established, and the relationship between lipid and carbohydrate metabolism indicators against the background of the use of antipsychotics and neuroleptics has not yet been studied enough.
About the Authors
N. N. Maksimiuk
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
D. S. Bogdashov
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
V. A. Baljasnaya
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
M. A. Nematjonov
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
References
1. Salekhov S.A., Korabelnikova I.A., Salekhova Yu.S., et al. Patogeneticheskoye obosnovaniye razvitiya neyrointoksikatsii posle psikhologicheskoy korrektsii [Pathogenetic substantiation of the development of neurointoxication after psychological correction]. Bulletin of the Novgorod State University, 2021, no. 1(122), pp. 54-57. doi: 10.34680/2076-8052.2021.1(122).54-57
2. Gorobets L.N., Bulanov V.S., Vasilenko L.M. Neyrolepticheskiye metabolicheskiye narusheniya pri lechenii antipsikhoticheskimi sredstvami novogo pokoleniya [Neuroleptic metabolic disorders in the treatment of new generation antipsychotic drugs]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakovav – S.S. Korsakov Journal of Neurology and Psychiatry, 2014, vol. 114(2), pp. 59-68.
3. Kibitov O.A., Mazo G.E. Metabolicheskiye pobochnyye effekty atipichnykh antipsikhotikov: mezhindividual'naya variabel'nost' i geneticheskiy risk [Metabolic side effects of atypical antipsychotics: interindividual variability and genetic risk]. Sotsial'naya i klinicheskaya psikhiatriya – Social and Clinical Psychiatry, 2018, vol. 28, no. 1, pp. 90-100.
4. Aleksandrovsky Yu.A., Neznanov N.G. Psikhiatriya: natsional'noye rukovodstvo. 2-ye izd., pererab. i dop [Psychiatry: a national guide. 2nd ed., red. and add]. Moscow, GEOTAR-Media Publ., 2018. 976 p.
5. Yastrebov D.V. Antipsikhoticheskaya terapiya s ispol'zovaniyem atipichnykh neyroleptikov [Antipsychotic therapy using atypical neuroleptics] Rossiyskiy psikhiatricheskiy zhurnal – Russian Psychiatric Journal, 2013, vol. 1, pp. 71-82.
6. Lyubov Ye.B., Mitina YU.V., Syumkina O.V., et al. Farmakoepidemiologicheskiy i farmakoekonomicheskiy analizy dlitel'nogo lecheniya atipichnymi antipsikhotikami bol'nykh shizofreniyey v povsednevnoy vnebol'nichnoy psikhiatricheskoy praktike [Pharmacoepidemiological and pharmacoeconomic analysis of long-term treatment with atypical antipsychotics in schizophrenic patients in everyday outpatient psychiatric practice]. Sotsial'naya i klinicheskaya psikhiatriya – Social and Clinical Psychiatry, 2010, vol. 20, no. 1, pp. 33-42.
7. Dunlop B.W., Sternberg M., Phillips L.S., et al. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull., 2003, vol. 37(3), pp. 99-117.
8. Farwell W.R., Stump T.E., Wang J., et al. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med., 2004, vol. 19(12), pp. 12001205. doi: 10.1111/j.1525-1497.2004.40126.x
9. Koro C.E., Fedder D.O., L'Italien G.J., et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry, 2002, vol. 59(11), pp. 10211026. doi: 10.1001/archpsyc.59.11.1021
10. Gothelf D. Falk B., Singer P., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry, 2002, vol. 159(6), pp. 10551057. doi: 10.1176/appi.ajp.159.6.1055
11. Ascher-Svanum H., Stensland M., Zhao Z., Kinon B.J. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry, 2005, vol. 5, article no. 3. doi: 10.1186/1471-244X-5-3
12. Ball M.P. Coons V.B., Buchanan R.W. A program for treating olanzapine-related weight gain. Psychiatr Serv., 2001, vol. 52(7), pp. 967-969. doi: 10.1176/appi.ps.52.7.967
13. Chang H.Y., Ridky T.W., Kimball A.B., et al. Eruptive xanthomas associated with olanzapine use. Arch Dermatol., 2003, vol. 139(8), pp. 1045-1048. doi: 10.1001/archderm.139.8.1045
14. Fraguas D., Kirchoff D. Pharmacogenetics of antipsychotic-induced weight gain. Med Sci Monit., 2006, vol. 12(5), pp. 6-7.
15. Lauressergues E., Martin F., Helleboid A. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch. Pharmacol., 2011, vol. 383, no. 4, pp. 423-436. doi: 10.1007/s00210-010-0597-3
16. Bai Y.M. Chen T.T., Yang W.S., et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr. Res., 2009, vol. 111, no. 1-3, pp. 1-8. doi: 10.1016/j.schres.2009.03.014
17. Chintoh A.F., Mann S.W., Lam L., et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr. Res., 2009, vol. 108, no. 1-3. pp. 127-133. doi: 10.1016/j.schres.2008.12.012
18. Isaac M.B., Isaac M.T. Olanzapine and weight gain. Am J Psychiatry, 2005, vol. 162(9), pp. 1764-1765. doi: 10.1176/appi.ajp.162.9.1764
19. Ray L.A., Heydari A., Zorick T. Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev., 2010, vol. 29(5), pp. 568-575. doi: 10.1111/j.1465-3362.2010.00185.x
20. Kibitov A.O., Ivaschenko D.V., Sychev D.A. Farmakogeneticheskiy podkhod k povysheniyu effektivnosti i bezopasnosti antipsikhoticheskoy farmakoterapii shizofrenii [Pharmacogenetic approach to improving the effectiveness and safety of antipsychotic pharmacotherapy of schizophrenia]. Sovremennaya terapiya psikhicheskikh rasstroystv – Modern therapy of mental disorders, 2017, no. 1, pp. 2 -13. doi: 10.21265/PSYPH.2017.40.4982
Review
For citations:
Maksimiuk N.N., Bogdashov D.S., Baljasnaya V.A., Nematjonov M.A. Influence of psychotpropic drugs on the state of lipid and carbohydrate exchange in patients. Title in english. 2022;(1(126)):81-85. (In Russ.) https://doi.org/10.34680/2076-8052.2022.1(126).81-85
Views:
33
Email this article 